Feasibility and acceptability of a primary care liver fibrosis testing pathway centred on the diabetes annual review: PRELUDE1 prospective cohort study protocol

INTRODUCTION: Non-alcoholic fatty liver disease is the most common chronic liver disease worldwide affecting 20%–25% in the USA and Europe with a 60%–80% lifetime prevalence for people with type 2 diabetes (T2D). Fibrosis has repeatedly been demonstrated to be the major determinant of liver disease...

Descripción completa

Detalles Bibliográficos
Autores principales: Brindley, James Hallimond, Abeysekera, Kushala, Hood, Gill, Jennings, Stacey, Moore, John, Hickman, Matthew, Alazawi, William
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
Gastroenterology and Hepatology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10201245/
https://www.ncbi.nlm.nih.gov/pubmed/37208139
http://dx.doi.org/10.1136/bmjopen-2022-066493

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10201245/
https://www.ncbi.nlm.nih.gov/pubmed/37208139
http://dx.doi.org/10.1136/bmjopen-2022-066493

Ejemplares similares